John Paulson bought $21.3M of Bausch Health Companies (BHC)
Executed Aug 11 2025, disclosed Aug 13 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 13 2025), the stock returned +2.8% (delay-adjusted); from the execution session (Aug 11 2025), +25.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
John Paulson (Director) filed 4 Form 4 reports in the past 24 months (4 purchases, 0 sales), most often in Bausch Health Companies Inc. (BHC). Across 4 priced purchase filings, the average 21-session return was +17.6% from execution and +8.1% from disclosure (delay-adjusted; derived). The largest single filing was $312.5M of BHC (34,721,118 sh × $9.00, as filed), executed Aug 14 2025.
Healthcare · Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→34,721,118 sh × $9.00
Exec Aug 14 2025
Filed Aug 14 2025 · 9:35 PM ET BHCPURCHASE Bausch Health Companies Inc. $21.2M
3,564,059 sh × $5.94
Exec Jun 13 2025
Filed Jun 17 2025 · 5:30 PM ET BHCPURCHASE Bausch Health Companies Inc. $14.7M
2,788,608 sh across 3 lots
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET